Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DynPort secures $32.3 million service contract from the NIAID

This article was originally published in Scrip

Executive Summary

DynPort Vaccine has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US NIH, to establish and operate a Phase I clinical trial unit for infectious disease therapeutics. The contract is valued at approximately $32.3 million over seven years. DynPort will team up with Quintiles Transnationalto complete the project. Under the agreement, DynPort and Quintiles will assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year. DynPort will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Quintiles will provide Phase I clinical research and support services. Work will be performed by DynPort at its headquarters in Maryland.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC003256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel